

## Portola Pharmaceuticals Inc

### COMPANY AND PIPELINE OVERVIEW REPORT

Coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 01-Feb-2014

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)

## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Financials..... 10

Product Portfolio Drugs..... 11

[Return to Table of Contents](#)

# Portola Pharmaceuticals Inc

## COMPANY OVERVIEW

|  |  |
|--|--|
| <b>Company Name</b>                          | Portola Pharmaceuticals Inc  |
| <b>Parent Company Name</b>                   | Portola Pharmaceuticals Inc  |
| <b>Website</b>                               | <a href="http://www.portola.com/">http://www.portola.com/</a>  |
| <b>Country</b>                               | US   |
| <b>Number of Drugs in Active Development</b> | 9  |
| <b>Number of Inactive Drugs</b>              | 2  |
| <b>Number of Patents as Owner</b>            | 51   |
| <b>Number of Patents as Third Party</b>      | 0  |
| <b>Number of Deals</b>                       | 13   |
| <b>Key Indications</b>                       | Rheumatoid arthritis, Inflammatory disease, Non-Hodgkin lymphoma, Cardiovascular disease, Coronary artery disease, Cancer, Chronic lymphocytic leukemia, Bleeding, Thrombosis, Allergy   |
| <b>Key Target-based Actions</b>              | Syk tyrosine kinase inhibitor, P2Y12 purinoceptor antagonist, Factor Xa antagonist, JAK tyrosine kinase inhibitor, Jak3 tyrosine kinase inhibitor, Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor, Factor Xa agonist, DNA polymerase alpha inhibitor, DNA primase inhibitor, Factor VIIa agonist, Factor X agonist, Ribonucleotide reductase inhibitor |
| <b>Key Technologies</b>                      | Small molecule therapeutic, Oral formulation, Intravenous formulation, Protein recombinant, Biological therapeutic, Infusion, Parenteral formulation unspecified, Stereochemistry, Drug combination, Peptide, Polynucleotide   |

## COMPANY PROFILE

### SUMMARY

Portola Pharmaceuticals Inc was spun-out from Millennium Pharmaceuticals in 2003 with cardiovascular technology formerly owned by COR Therapeutics, which was acquired by, and merged into, Millennium in February 2002. Portola is a privately-held biopharmaceutical company focused on the discovery and development of therapeutics for the treatment and prevention of severe cardiovascular diseases, especially thrombosis. Its R&D is particularly focused on well validated targets in order to reduce safety and efficacy risks. Portola is currently interested to inlicense cardiology or inflammation treatments.

### COMPANY LOCATION

Portola is located in South San Francisco, CA.

### LICENSING AGREEMENTS

In June 2005, Portola and Astellas entered a license agreement to develop a selection Astellas's preclinical cardiovascular compounds.

### FINANCIAL

In October 2013, Portola began an underwritten public offering of its common stock shares and was to raise approximately \$100 million from the offering. Also, the offering would include shares from certain existing shareholders. Later that month, the company raised \$100 million by the closing of the offering.

In October 2013, a lock-up restriction of 95,962 shares of the company's common stock was released.

In April 2013, Portola was planning an IPO of its stock. In May 2013, Portola priced the offering of 8,422,758 shares of its common stock at a price of \$14.50 each. The underwriters were granted a 30-day over-allotment option to purchase up to an additional 1,263,413 shares at the offering price. The shares were expected to begin trading on the NASDAQ Global Market on May 22, 2013 under the trading symbol 'PTLA' and the offering was expected to close on May 28, 2013. Later that month, the offering was closed and raised net proceeds of \$126 million. In December 2013, NASDAQ reported that, Portola would be added to the NASDAQ Biotechnology Index, as a result of the annual re-ranking under

[Return to Table of Contents](#)



the trading symbol 'PTLA', which would become effective prior to market open on December 23, 2013.

In November 2011, the company raised \$89 million in a preferred stock financing.

In July 2008, the company raised \$60 million in a preferred stock financing.

In May 2007, Portola raised \$70 million in a series C preferred stock financing.

In October 2006, Portola secured \$20 million in debt financing from Hercules Technology Growth Capital. The company planned to use the funds to advance development of its pipeline candidates.

In November 2005, Portola raised \$46 million in a series B financing.


In December 2003, Portola raised \$21 million in its series A financing round. The company intended to use the funding to support its R&D program in vascular thrombosis and inflammation underlying atherosclerosis.

## PRODUCT PORTFOLIO SUMMARY

### DRUGS

#### Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

## Drugs by Indication Table

| Indication              | Active | Inactive | Total |
|-------------------------|--------|----------|-------|
| Cardiovascular disease  | 5      | 3        | 8     |
| Hematological disease   | 4      | 0        | 4     |
| Neoplasm                | 4      | 0        | 4     |
| Inflammatory disease    | 3      | 0        | 3     |
| Musculoskeletal disease | 2      | 0        | 2     |
| Immune disorder         | 2      | 0        | 2     |
| Neurological disease    | 0      | 1        | 1     |
| Metabolic disorder      | 1      | 0        | 1     |
| Dermatological disease  | 1      | 0        | 1     |

## Drugs by Highest Status

### Active Drugs by Highest Status Chart



[Return to Table of Contents](#)

## Drugs by Highest Status Table

| Development Status      | Number of Drugs |
|-------------------------|-----------------|
| Phase 3 Clinical        | 1               |
| Phase 2 Clinical        | 3               |
| Discovery               | 2               |
| Suspended               | 3               |
| No Development Reported | 2               |

## DEALS

| Deal Type                                    | Principal |          | Partner |          | Total |
|--|-----------|----------|---------|----------|-------|
|  | Active    | Inactive | Active  | Inactive |       |
| Drug - Screening/Evaluation                  | 0         | 0        | 2       | 0        | 2     |
| Drug - Early Research/Development            | 1         | 0        | 0       | 0        | 1     |
| Drug - Development/Commercialization License | 3         | 0        | 2       | 0        | 6     |
| Drug - Development Services                  | 3         | 0        | 1       | 0        | 4     |

## CLINICAL TRIALS

### Trials by Condition Studied

| Condition Studied      | Ongoing | All |
|------------------------|---------|-----|
| Cardiovascular disease | 1       | 11  |
| Hematological disease  | 1       | 10  |
| Immune disorder        | 0       | 2   |
| Neoplasm               | 0       | 2   |
| Genitourinary disease  | 0       | 1   |
| Neurological disease   | 0       | 1   |

### Trials by Phase

| Phase               | Ongoing | All |
|---------------------|---------|-----|
| Phase 3             | 1       | 2   |
| Phase 2             | 0       | 6   |
| Phase 1             | 0       | 12  |
| Phase not specified | 1       | 2   |

[Return to Table of Contents](#)





## Phase Definitions

### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

| Indication                     | As Owner | As Third Party | Total |
|--------------------------------|----------|----------------|-------|
| Cardiovascular disease         | 49       | 0              | 49    |
| Endocrine disease              | 8        | 0              | 8     |
| Gastrointestinal disease       | 10       | 0              | 10    |
| Growth disorder                | 1        | 0              | 1     |
| Hematological disease          | 42       | 0              | 42    |
| Degeneration                   | 2        | 0              | 2     |
| Immune disorder                | 15       | 0              | 15    |
| Psychiatric disorder           | 2        | 0              | 2     |
| Musculoskeletal disease        | 12       | 0              | 12    |
| Neoplasm                       | 13       | 0              | 13    |
| Ocular disease                 | 6        | 0              | 6     |
| Genetic disorder               | 8        | 0              | 8     |
| Metabolic disorder             | 11       | 0              | 11    |
| Mouth disease                  | 6        | 0              | 6     |
| Neurological disease           | 27       | 0              | 27    |
| Respiratory disease            | 4        | 0              | 4     |
| Inflammatory disease           | 15       | 0              | 15    |
| Otorhinolaryngological disease | 1        | 0              | 1     |
| Gynecology and obstetrics      | 2        | 0              | 2     |
| Dermatological disease         | 7        | 0              | 7     |


\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



PRODUCT PORTFOLIO FINANCIALS

DRUG SALES AND FORECASTS



Drug Sales as a Share of the Total Sales 2016



[Return to Table of Contents](#)

## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### betrixaban

|                             |  |
|-----------------------------|--|
| <b>Drug Name</b>            | betrixaban   |
| <b>Key Synonyms</b>         | betrixaban   |
| <b>Originator Company</b>   | Takeda Pharmaceutical Co Ltd   |
| <b>Active Companies</b>     | Lee's Pharmaceutical Holdings (Hong Kong) Ltd, Portola Pharmaceuticals Inc       |
| <b>Inactive Companies</b>   | Merck & Co Inc, Millennium Pharmaceuticals Inc                                   |
| <b>Highest Status</b>       | Phase 3 Clinical   |
| <b>Active Indications</b>   | Phlebothrombosis, Thromboembolism  |
| <b>Target-based Actions</b> | Factor Xa antagonist   |
| <b>Other Actions</b>        | Neuroprotectant, Coagulation inhibitor   |
| <b>Technologies</b>         | Oral formulation, Oral sustained release formulation, Small molecule therapeutic |
| <b>Last Change Date</b>     | 14-Jan-2014  |

### andexanet alfa

|                             |  |
|-----------------------------|--|
| <b>Drug Name</b>            | andexanet alfa   |
| <b>Key Synonyms</b>         | andexanet alfa   |
| <b>Originator Company</b>   | Portola Pharmaceuticals Inc  |
| <b>Active Companies</b>     | Portola Pharmaceuticals Inc  |
| <b>Inactive Companies</b>   |  |
| <b>Highest Status</b>       | Phase 2 Clinical   |
| <b>Active Indications</b>   | Bleeding   |
| <b>Target-based Actions</b> | Factor Xa antagonist   |
| <b>Other Actions</b>        | Antidote, Coagulation stimulator   |
| <b>Technologies</b>         | Intravenous formulation, Infusion, Biological therapeutic, Parenteral formulation unspecified, Protein recombinant |
| <b>Last Change Date</b>     | 14-Jan-2014  |

[Return to Table of Contents](#)

## cerdulatinib

|                             |  |
|-----------------------------|--|
| <b>Drug Name</b>            | cerdulatinib   |
| <b>Key Synonyms</b>         | cerdulatinib   |
| <b>Originator Company</b>   | Portola Pharmaceuticals Inc  |
| <b>Active Companies</b>     | Aciex Therapeutics Inc, Portola Pharmaceuticals Inc                                      |
| <b>Inactive Companies</b>   |  |
| <b>Highest Status</b>       | Phase 2 Clinical   |
| <b>Active Indications</b>   | Non-Hodgkin lymphoma, Ocular disease, Chronic lymphocytic leukemia, Rheumatoid arthritis |
| <b>Target-based Actions</b> | JAK tyrosine kinase inhibitor, Syk tyrosine kinase inhibitor                             |
| <b>Other Actions</b>        | Apoptosis stimulator, Anticancer protein kinase inhibitor, Anti-inflammatory             |
| <b>Technologies</b>         | Oral formulation, Small molecule therapeutic   |
| <b>Last Change Date</b>     | 14-Jan-2014  |

## PRT-2607

|                             |   |
|-----------------------------|---|
| <b>Drug Name</b>            | PRT-2607  |
| <b>Key Synonyms</b>         |   |
| <b>Originator Company</b>   | Portola Pharmaceuticals Inc   |
| <b>Active Companies</b>     | Portola Pharmaceuticals Inc, Biogen Idec Inc  |
| <b>Inactive Companies</b>   |   |
| <b>Highest Status</b>       | Phase 2 Clinical  |
| <b>Active Indications</b>   | Chronic lymphocytic leukemia, Rheumatoid arthritis, Allergy, Systemic lupus erythematosus, Non-Hodgkin lymphoma, Cancer, Inflammatory disease |
| <b>Target-based Actions</b> | Syk tyrosine kinase inhibitor   |
| <b>Other Actions</b>        | Coagulation inhibitor, Anticancer protein kinase inhibitor, Anti-inflammatory   |
| <b>Technologies</b>         | Oral formulation, Small molecule therapeutic  |
| <b>Last Change Date</b>     | 20-Aug-2013   |

[Return to Table of Contents](#)



**PRT-060318**

|                             |   |
|-----------------------------|---|
| <b>Drug Name</b>            | PRT-060318  |
| <b>Key Synonyms</b>         |   |
| <b>Originator Company</b>   | Portola Pharmaceuticals Inc   |
| <b>Active Companies</b>     | Portola Pharmaceuticals Inc   |
| <b>Inactive Companies</b>   |   |
| <b>Highest Status</b>       | Discovery   |
| <b>Active Indications</b>   | B-cell acute lymphoblastic leukemia, Heparin induced thrombocytopenia |
| <b>Target-based Actions</b> | Syk tyrosine kinase inhibitor   |
| <b>Other Actions</b>        | Anticancer protein kinase inhibitor, Coagulation inhibitor            |
| <b>Technologies</b>         | Oral formulation, Small molecule therapeutic                          |
| <b>Last Change Date</b>     | 08-Jan-2013   |

**JAK tyrosine kinase inhibitors (oral, inflammatory disease/myelodysplastic syndromes), Portola**

|                             |  |
|-----------------------------|--|
| <b>Drug Name</b>            | JAK tyrosine kinase inhibitors (oral, inflammatory disease/myelodysplastic syndromes), Portola |
| <b>Key Synonyms</b>         |  |
| <b>Originator Company</b>   | Portola Pharmaceuticals Inc  |
| <b>Active Companies</b>     | Portola Pharmaceuticals Inc  |
| <b>Inactive Companies</b>   |  |
| <b>Highest Status</b>       | Discovery  |
| <b>Active Indications</b>   | Inflammatory disease, Myelodysplastic syndrome   |
| <b>Target-based Actions</b> | Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor, Jak3 tyrosine kinase inhibitor |
| <b>Other Actions</b>        | Anti-inflammatory, Anticancer  |
| <b>Technologies</b>         | Oral formulation, Small molecule therapeutic   |
| <b>Last Change Date</b>     | 17-Jan-2012  |

[Return to Table of Contents](#)


### non-sulfonylurea P2Y12 antagonists (cardiovascular disease), Portola

|                             |  |
|-----------------------------|--|
| <b>Drug Name</b>            | non-sulfonylurea P2Y12 antagonists (cardiovascular disease), Portola |
| <b>Key Synonyms</b>         |  |
| <b>Originator Company</b>   | Portola Pharmaceuticals Inc  |
| <b>Active Companies</b>     | Portola Pharmaceuticals Inc  |
| <b>Inactive Companies</b>   |  |
| <b>Highest Status</b>       | Suspended  |
| <b>Active Indications</b>   | Cardiovascular disease   |
| <b>Target-based Actions</b> | P2Y12 purinoceptor antagonist  |
| <b>Other Actions</b>        | Platelet aggregation inhibitor, Coagulation inhibitor                |
| <b>Technologies</b>         | Stereochemistry, Small molecule therapeutic                          |
| <b>Last Change Date</b>     | 25-Sep-2009  |

### elinogrel (oral, cardiovascular events), Portola/Novartis

|                             |   |
|-----------------------------|---|
| <b>Drug Name</b>            | elinogrel (oral, cardiovascular events), Portola/Novartis |
| <b>Key Synonyms</b>         | elinogrel, elinogrel potassium                            |
| <b>Originator Company</b>   | Portola Pharmaceuticals Inc                               |
| <b>Active Companies</b>     | Portola Pharmaceuticals Inc                               |
| <b>Inactive Companies</b>   | Novartis AG   |
| <b>Highest Status</b>       | Suspended   |
| <b>Active Indications</b>   | Coronary artery disease                                   |
| <b>Target-based Actions</b> | P2Y12 purinoceptor antagonist                             |
| <b>Other Actions</b>        | Coagulation inhibitor, Platelet aggregation inhibitor     |
| <b>Technologies</b>         | Oral formulation, Small molecule therapeutic              |
| <b>Last Change Date</b>     | 16-Aug-2012   |

[Return to Table of Contents](#)

### elinogrel (intravenous, cardiovascular events), Portola/Novartis

|                             |  |
|-----------------------------|--|
| <b>Drug Name</b>            | elinogrel (intravenous, cardiovascular events), Portola/Novartis |
| <b>Key Synonyms</b>         | elinogrel potassium, elinogrel                                   |
| <b>Originator Company</b>   | Portola Pharmaceuticals Inc                                      |
| <b>Active Companies</b>     | Portola Pharmaceuticals Inc                                      |
| <b>Inactive Companies</b>   | Novartis AG  |
| <b>Highest Status</b>       | Suspended  |
| <b>Active Indications</b>   | Coronary artery disease  |
| <b>Target-based Actions</b> | P2Y12 purinoceptor antagonist                                    |
| <b>Other Actions</b>        | Coagulation inhibitor, Platelet aggregation inhibitor            |
| <b>Technologies</b>         | Intravenous formulation, Small molecule therapeutic              |
| <b>Last Change Date</b>     | 16-Aug-2012  |

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

